From: Translatability scoring in drug development: eight case studies
Compound | Dabigatran | Ipilimumab | Gefitinib | Gefitinib* | Vilazodone | Latrepirdine | Semegacestat | Torcetrapib[37] | Varenicline[37] |
---|---|---|---|---|---|---|---|---|---|
Aspect | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Starting evidence | Â | Â | Â | Â | Â | Â | Â | Â | Â |
In vitro data Including animal genetics | 0.1 [4] | 0.06 [38] | 0.08 [41] | 0.1 [12] | 0.1 | 0.1 | |||
In vivo data Including animal genetics | 0.15 [4] | 0.15 | 0.15 | ||||||
Animal disease models | 0.09 [51] | 0.09 [1] | 0.09 [1] | 0.06 [49] | 0.03 [18] | 0.12 | 0.15 | ||
Data from multiple species | 0.15 [4] | 0.09 [46] | 0.06 [54] | 0.06 [54] | 0.03 [42] | 0.15 [12] | 0.03 | 0.15 | |
Human evidence | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Genetics | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | ||
Model Compounds | 0.52 [60] | 0.52 [61] | 0.13 [54] | 0.13 [54] | 0.13 | Â | 0.65 | ||
Clinical trials | 0.26 | 0.52 | |||||||
Biomarkers for efficacy and safety prediction | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Biomarker Grading | 0.96 [5] | 0 | 0 [23] | 0.48 | 1.2 | ||||
Biomarker development | 0.26 | 0.52 [5] | 0 | 0 [23] | 0.26 | 0.52 | |||
Proof-of-mechanism, proof-of-principle and proof of concept testing | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Biomarker strategy | 0.2 [5] | 0 | 0 [23] | 0.1 | 0.25 | ||||
Surrogate or endpoint strategy | 0.4 | 0.4 [5] | 0 | 0 [23] | 0.16 | 0.32 | |||
Personalized medicine aspects | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Disease sub-classification and responder concentration | 0.12 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.09 | 0.03 | |
Pharmacogenetics | 0.25 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.15 | 0.05 | |
Sum | 3.77 | 3.65 | 2.54 | 4.25 | 2.6 | 0.60 (0) | 1.28 (0) | 1.95 | 4.14 |